AlTahan Abdulrahman M, Berger Thomas, AlOrainy Ibrahim A, AlTahan Husam
Department of Neurology, King Saud University, Riyadh, Saudi Arabia.
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Am J Case Rep. 2019 Jan 24;20:101-105. doi: 10.12659/AJCR.911521.
BACKGROUND Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infectious disease with high morbidity and mortality. Its incidence in multiple sclerosis (MS) patients has risen since the introduction of disease modifying drugs. In the absence of a specific treatment, the outcome depends heavily on early diagnosis, which illustrates the importance of the role of characteristic brain magnetic resonance imaging (MRI). However, when relying mainly on MRI, the diagnosis of cases with atypical radiological changes may be missed or delayed. CASE REPORT A 32-year-old female diagnosed with elapsing remitting MS in 2009 was started on interferon-beta-1b that was escalated to natalizumab due to progression of the disease. Later, she was shifted to fingolimod as testing for John Cunningham polyoma virus (JCV) antibodies was positive. Three years later, she presented with a 3-week history of progressive walking impairment associated with twitching of her facial muscles and abnormal sensation all over her body that was associated with left hemi-paresis and sensory changes, in addition to truncal ataxia, which was treated with steroids as a relapse of MS. However, the patient continued to deteriorate and developed significant cognitive and behavioral changes. In view of this clinical picture, the diagnosis of PML was raised in spite of her atypical brain MRI features. Treatment with fingolimod was stopped and a sample of her cerebrospinal fluid was sent for JCV DNA analysis, which came back positive at 11 copies/mL. Treatment with mirtazepine and mefloquine was started, but the patient deteriorated further, and MRI showed severe changes consistent with immune reconstitution inflammatory syndrome. Intravenous steroids and intravenous immunoglobulin were given, and within a few weeks, the patient was stabilized and started to gradually improve. CONCLUSIONS In patients at risk for developing PML who present with typical clinical features, testing for JCV DNA is recommended even in the absence of typical radiological findings in order to prevent any delay in the diagnosis.
背景 进行性多灶性白质脑病(PML)是一种严重的机会性传染病,发病率和死亡率都很高。自从引入疾病修饰药物以来,其在多发性硬化症(MS)患者中的发病率有所上升。在缺乏特异性治疗的情况下,预后很大程度上取决于早期诊断,这说明了特征性脑磁共振成像(MRI)作用的重要性。然而,主要依靠MRI时,非典型放射学改变病例的诊断可能会被漏诊或延误。病例报告 一名32岁女性于2009年被诊断为复发缓解型MS,开始使用β-1b干扰素治疗,后因病情进展升级为那他珠单抗。后来,由于约翰·坎宁安多瘤病毒(JCV)抗体检测呈阳性,她改用芬戈莫德。三年后,她出现了3周的进行性行走障碍病史,伴有面部肌肉抽搐和全身异常感觉,并伴有左侧偏瘫和感觉改变,此外还有躯干共济失调,最初作为MS复发用类固醇治疗。然而,患者病情持续恶化,出现了明显的认知和行为改变。鉴于此临床表现,尽管她的脑MRI特征不典型,但仍怀疑为PML。停用芬戈莫德治疗,并送检其脑脊液样本进行JCV DNA分析,结果为11拷贝/mL,呈阳性。开始使用米氮平和甲氟喹治疗,但患者病情进一步恶化,MRI显示与免疫重建炎症综合征一致的严重改变。给予静脉注射类固醇和静脉注射免疫球蛋白,几周内患者病情稳定并开始逐渐好转。结论 对于有发生PML风险且出现典型临床特征的患者,即使没有典型的放射学表现,也建议进行JCV DNA检测,以防止诊断延误。